Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Akebia Therapeutics ( (AKBA) ).
Akebia Therapeutics has entered a multi-year commercial supply agreement with a leading dialysis organization to provide access to its drug Vafseo® (vadadustat) for dialysis patients. This strategic move could enhance Akebia’s market presence in the dialysis segment, offering potential growth opportunities.
Learn more about AKBA stock on TipRanks’ Stock Analysis page.